Article: Street avoids terms like 'sell'

Dear Mr. Berko: A good friend recently bought 1,000 shares of CytRx Corp. because of a pending medical discovery that might be effective against amyotrophic lateral sclerosis and diabetes. I'd like your thoughts on purchasing 1,000 shares. It's a cheap stock and trades at $3.96 a share.

But my major question is about my daughter's account at Wachovia. She was told in February to buy 500 shares of Beazer Homes when Wachovia's research recommended the stock at $45. She did and it's now $37.47 and she's down eight points, or $3,765. I think she should sue Wachovia for two reasons: The housing industry was in awful shape when the Beazer recommendation was issued and when the stock started ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!